Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation.
Recombinant human erythropoietin (rHu EPO) has been reported to accelerate early erythroid reconstitution after bone marrow transplantation (BMT). We conducted a pilot study on rHu EPO for late-onset anemia in 9 patients after allogeneic BMT. The patients achieved initial erythropoietic recovery (hemoglobin (Hb) range 9.1-13.4, mean 10.8 g/dl), but then developed transplant-related anemia (Hb range 6.3-9.7, mean 8.2 g/dl) more than 50 days after BMT. This type of anemia was related to graft-versus-host disease (GVHD), cytomegalovirus infection, and/or impaired EPO secretion. The patients received 3,000 or 12,000 U of rHu EPO subcutaneously three or seven times weekly. Hb levels increased by more than 2 g/dl in 6 of the 9 patients, but were unchanged in the 3 patients with severe GVHD. These findings suggest that in some cases rHu EPO is effective for the treatment of late-onset anemia after BMT.
Fujimori
Y
Y
Second Department of Internal Medicine, Hyogo College of Medicine, Japan.
Kanamaru
A
A
Saheki
K
K
Mori
A
A
Takatsuka
H
H
Wada
H
H
Okada
M
M
Tamura
S
S
Okamoto
T
T
Takemoto
Y
Y
Kakishita
E
E
Nagai
K
K
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004921:Erythropoietin / Q000235:genetics* / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects
D011994:Recombinant Proteins; D004921:Erythropoietin